A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease

Trial Profile

A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Jun 2018

At a glance

  • Drugs Abiraterone acetate (Primary) ; Prednisone
  • Indications Prostate cancer
  • Focus Proof of concept; Therapeutic Use
  • Acronyms IMAAGEN
  • Sponsors Janssen Biotech
  • Most Recent Events

    • 06 Apr 2018 Results (Data cut off 13 Oct 2015) assessing safety and efficacy published in the Journal of Urology
    • 10 Jun 2017 Biomarkers information updated
    • 07 Jun 2016 Results analyzing safety and other secondary endpoints, presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top